{"597237":{"#nid":"597237","#data":{"type":"event","title":"Cell Manufacturing and Immunoengineering Seminar","body":[{"value":"\u003Cp\u003E\u003Cstrong\u003E\u0026quot;Chimeric Antigen Receptor T Cells: Clinical Development, FDA Approval, and What\u0026rsquo;s Coming Next\u0026quot;\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EBruce Levine, Ph.D.\u003Cbr \/\u003E\r\nBarbara and Edward Netter Professor in Cancer Gene Therapy\u003Cbr \/\u003E\r\nUniversity of Pennsylvania Perelman School of Medicine\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ESince the 1990\u0026rsquo;s, we have conducted clinical trials of gene modified T cells. Chimeric antigen receptor (CAR) T cells targeting CD19 on B cells leukemias and lymphomas have induced durable complete responses in patients who are relapsed or refractory to all other available treatments.\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EThis synthetic biology technology has now undergone global multi-center clinical trials and recently received FDA approval (Kymriah\u003Csup\u003ETM\u003C\/sup\u003E, Novartis) in relapsed\/refractory acute lymphoid leukemia in children and young adults.\u0026nbsp;CAR T cells targeting new targets in hematologic malignancies and in solid tumors are underway and provide demonstration that it is possible to design immunity at will for therapeutic application.\u0026nbsp;\u0026nbsp;\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"\u0022Chimeric Antigen Receptor T Cells: Clinical Development, FDA Approval, and What\u2019s Coming Next\u0022 - Bruce Levine, Ph.D., University of Pennsylvania"}],"uid":"27561","created_gmt":"2017-10-11 18:02:18","changed_gmt":"2017-10-12 18:44:17","author":"Angela Ayers","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2017-12-08T11:00:00-05:00","event_time_end":"2017-12-08T12:00:00-05:00","event_time_end_last":"2017-12-08T12:00:00-05:00","gmt_time_start":"2017-12-08 16:00:00","gmt_time_end":"2017-12-08 17:00:00","gmt_time_end_last":"2017-12-08 17:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"},{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"}],"categories":[],"keywords":[{"id":"126571","name":"go-PetitInstitute"},{"id":"126221","name":"go-immuno"},{"id":"168084","name":"go-rem-events"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1795","name":"Seminar\/Lecture\/Colloquium"}],"invited_audience":[{"id":"78761","name":"Faculty\/Staff"},{"id":"78771","name":"Public"},{"id":"174045","name":"Graduate students"},{"id":"78751","name":"Undergraduate students"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}